Comparative Pharmacology
Head-to-head clinical analysis: ALLAY versus DOXY SLEEP AID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLAY versus DOXY SLEEP AID.
ALLAY vs DOXY-SLEEP-AID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALLAY (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
Doxy-Sleep-Aid is a sedative-hypnotic drug that acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA. It selectively binds to α1 subunits of GABA-A receptors, promoting sleep onset and maintenance.
ALLAY is a brand name for metoclopramide. Typical adult dose: 10 mg orally 4 times daily (30 minutes before meals and at bedtime). Alternatively, 10 mg intramuscularly or intravenously over 1-2 minutes. Maximum 30 mg/day (except for treatment of chemotherapy-induced emesis: 1-2 mg/kg IV 30 minutes before chemotherapy, then every 2 hours for 2 doses, then every 3 hours for 3 doses).
Doxylamine succinate 25 mg orally once daily at bedtime.
None Documented
None Documented
Terminal half-life 8-12 hours in adults; prolonged to 18-24 hours in elderly or moderate hepatic impairment (Child-Pugh class B).
10-12 hours; extended in elderly and hepatic impairment
Primarily renal excretion of unchanged drug (60-70%) and glucuronidated metabolites (10-15%); biliary/fecal elimination accounts for 10-20%.
Renal: 40% unchanged; biliary/fecal: 60% as metabolites
Category C
Category C
Antihistamine (Sedating)
Antihistamine (Sedating)